Strides Pharma Q2 Net Profit Rises to ₹1.28 Billion; Revenue Grows to ₹12.21 Billion on US Market Momentum

Strides Pharma Science Ltd has posted a solid recovery in its Q2 FY2026 financial results, marking a return to profitability after a challenging previous year. The company reported a consolidated revenue of ₹12.21 billion, up from ₹11.01 billion YoY, supported by robust performance in the US market and new product launches.

Net profit surged to ₹1.28 billion, reversing a net loss of ₹1.49 billion in the same quarter last year. The turnaround was attributed to cost optimization, portfolio expansion, and strategic focus on regulated markets. Strides also saw improved operating margins of 15.1%, reflecting better product mix and manufacturing efficiencies.

The company continues to invest in R&D and capacity expansion, with a pipeline of differentiated products targeting chronic therapies and injectables. Management remains optimistic about sustained growth in H2 FY2026, citing strong demand and regulatory tailwinds.

Key Highlights:

Revenue from Operations: ₹12.21 billion

Net Profit: ₹1.28 billion (vs. ₹1.49 billion loss YoY)

Operating Margin: 15.1%

Growth Drivers: US generics, new launches, cost control

Strategic Focus: Chronic therapies, injectables, regulated markets

Outlook: Positive on margin expansion and product pipeline

Strides Pharma’s Q2 results reflect a strategic rebound and renewed momentum in global generics.

Sources: Economic Times, LiveMint